Onset of action and seizure control in Lennox-Gaustaut syndrome: Focus on rufinamide

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 271-280

  Saneto, Russell P ^a   Anderson, Gail D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Catastrophic pediatric epilepsy; Lennox Gaustaut syndrome; Rufinamide

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CGP 47292; DRUG METABOLITE; FELBAMATE; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; RUFINAMIDE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VIGABATRIN;

ABSENCE; ADD ON THERAPY; APLASTIC ANEMIA; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; COORDINATION DISORDER; DIPLOPIA; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; EPILEPTIC STATE; FATIGUE; FEVER; GENERALIZED EPILEPSY; GLAUCOMA; GRAND MAL SEIZURE; HIGH RISK PATIENT; HUMAN; HYPERSALIVATION; HYPERTHERMIA; LENNOX GASTAUT SYNDROME; LIVER FAILURE; MENTAL DISEASE; METABOLIC ACIDOSIS; MORBIDITY; MYOCLONUS SEIZURE; NAUSEA; NONHUMAN; OLIGOHYDROSIS; PATIENT CARE; QT INTERVAL; REVIEW; SEIZURE; SHORT QT SYNDROME; SIDE EFFECT; SKIN TOXICITY; SOMNOLENCE; TONIC CLONIC SEIZURE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 77949457293     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/tcrm.s4282     Document Type: Review

References (54)

1. Aicardi J, Levy Gomes A. Clinical and electroencephalographic symptomatology of the 'genuine' Lennox-Gastaut syndrome and its differentiation from other forms of epilepsy of early childhood. Epilepsy Res. 1992;6:185-193.
2. Fitzgerald LF, Stone JL, Hughes JR, Melyn MA, Lansky LL. The Lennox-Gastaut syndrome: electroencephalographic characteristics, clinical correlates, and follow-up studies. Clinical Encephalogr. 1992;23(4):180-189.
3. Markand ON. Lennox-Gastaut syndrome (childhood epileptic encephalopathy). J Clin Neurophysiol. 2003;20(6):426-441.
4. Genton P, Guerrine R, Dravet C. The Lennox-Gaustaut syndrome. In: Meinardi H, editor. Handbook of Clinical Neurology: The Epilepsies, Part II. Amsterdam: Elsevier Science. 2000;73:211-222.
5. Goldsmith IL, Zupanc ML, Buchhalter JR. Long-term seizure outcome in 74 patients with Lennox-Gastaut syndrome: effects of incorporating MRI head imaging in defining the cryptogenic subgroup. Epilepsia. 2000;41(4):395-399.
6. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008;70(21):1950-1958.
7. Gibbs FA, Gibbs EL, Lennox WG. The influence of the blood sugar level on the wave and spike formation in petit mal epilepsy. Arch Neurol Psychiat. 1939;41:1111-1116.
8. Lennox WG, Davis JP. Clinical correlates of the fast and the slow spike-wave electroencephalogram. Pediatrics. 1950;5(4):626-644.
9. Dravet C. Encephalopathic Epileptique de l'Enfant avec Pointe-Onde Lente Diffuse [dissertation]. University of Marseille, France. 1965.
10. Gastraut H, Roger J, Soulayrol R, et al. Childhood epileptic encephalopathy with diffuse slow spike-waves (otherwise known as "petit mal variant") or Lennox syndrome. Epilepsia. 1966;7(2):139-179.
11. Ohtahara S, Ohtsuka Y, Kobayashi K. Lennox-Gastaut syndrome: a new vista. Psychiatry and Clin Neurosci. 1995;49(3):S179-S183.
12. Roger J, Dravet C, Bureau M. The Lennox-Gaustaut syndrome. Cleveland Clin J Med. 1989;56(Suppl Pt 2):S172-S180.
13. Bauer G, Benke T, Bohr K. The Lennox-Gaustaut syndrome in adulthood. In: Niedermeyer E, Degen R, editors. The Lennox-Gaustaut Syndrome. New York: Alan R. Liss Inc; 1988. p. 317-328.
14. Guerrini R, Dravet C, Ferrari AR, Battaglia A. The evolution of epilepsy in the most common genetic forms with mental retadrdation (Down's syndrome and fragile X syndrome). Pediatr Med Chir. 1993;15(Suppl 1):19-22.
15. Beaumanoir A. The Lennox-Gastaut syndrome: a personal study. Electroencephalogr Clin Neurophysiol. 1982(35):85-99.
16. Bearmanoir A, Dravet CIeLJLp-. The Lennox-Gastaut syndrome. In: Roger J, Dureau M, Dravet C, Dreifuss FE, Perret A, Wolf P, eds. Epileptic syndromes in infancy, childhood and adolescence. 1992. 2nd ed. London: John Libbey; 1992. p. 115-132.
17. Trevathan E. Infantile spasms and Lennox-Gastaut syndrome. J Child Neurol. 2002;17 Suppl 2:2S9-2S22.
18. Markand ON. Slow spike-wave activity in EEG and associated clinical features: often called 'Lennox' or "Lennox-Gastaut" syndrome. Neurology. 1977;27(8):746-757.
19. Oguni H, Hayashi K, Osawa M. Long-term prognosis of Lennox-Gastaut syndrome. Epilepsia. 1996;37 Suppl 3:44-47.
20. Aicardi J, Gomes AL. The Lennox-Gaustaut syndrome. Clinical and electroencephalographic features. In: Niedermeyer E, Degen R, editors. The Lennox-Gaustaut Syndrome. New York: Alan R. Liss; 1988. p. 25-46.
21. Ohtahara S, Ohtsuka Y, Yamatogi Y, et al. Early infantile epileptic encephalopathy with suppression-burst. In: Roger J, Bureau M, Dravet C, Dreifuss PE, Peret A, Wolf P, editors. Epileptic syndromes in infancy, childhood, and adolescence. 2nd ed. London: John Libbey; 1992. p. 25-34.
22. Chevrie JJ, Aicardi J. Childhood epileptic encephalopathy with slow spike-wave. A statistical study of 80 cases. Epilepsia. 1972;13(2): 259-271.
23. Ikeno T, Shigematsu H, Miyakoshi M, Ohba A, Yagi K, Seino M. An analytic study of epileptic falls. Epilepsia. 1985;26(6):612-621.
24. Egli M, Mothersill I, O'Kane M, O'Kane F. The axial spasm - the predominant type of drop seizure in patients with secondary generalized epilepsy. Epilepsia. 1985;26(5):401-415.
25. Bittencourt PR, Richens A. Anticonvulsant-induced status epilepticus in Lennox-Gastaut syndrome. Epilepsia. 1981;22(1):129-134.
26. DiMario FJ Jr, Clancy RR. Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures. Pediatr Neurol. 1988;4(4):249-251.
27. Beaumanoir A, Foletti G, Magistris M, Volanschi D. Status epilepticus in the Lennox-Gastaut syndrome. In: Niedermeyer E, Degen R, editors. The Lennox-Gaustaut Syndrome. New York: Alan R. Liss; 1988. p. 283-300.
28. Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med. 1997;337(25):1807-1812.
29. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). The Felbamate Study Group in Lennox-Gastaut Syndrome. N Engl J Med. 1993;328(1):29-33.
30. Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A doubleblind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology. 1999;52(9):1882-1887.
31. Hancock E, Cross H. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev. 2003;(3):CD003277.
32. Frost M, Gates J, Helmers SL, et al. Vagus nerve stimulation in children with refractory seizures associated with Lennox-Gastaut syndrome. Epilepsia. 2001;42(9):1148-1152.
33. Maehara T, Shimizu H. Surgical outcome of corpus callosotomy in patients with drop attacks. Epilepsia. 2001;42(1):67-71.
34. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res. 2001;43:11-58.
35. McLean MHJ, Schmutz M, Pozza M, et al. The influence of rufinamide on sodium currents and action potential firing in rodent neurons. [abstract]. Epilepsia. 2005;46(Suppl 8):296.
36. White HS, Schmutz M, Pozza M, Wolf H, Stables J, Kupfererg H. The anticonvulsant profile and tolerability of rufinamide in mice and rats (abstract). Epilepsia. 2005;46 Suppl 8:280.
37. Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008;49(7):1123-1141.
38. Arroyo S. Rufinamide. Neurotherapeutics. 2007;4:155-162.
39. Glauser T, Bialer M. Rufinamide. In: Pedley T, Engle J, editors. Epilepsy: a comprehensive textbook. 2nd ed. Philadelphia: Wolter/ Kluwer/Lippincott Williams and Wilkins; 2007. p. 1647-1654.
40. Waldmeier F, Gschwind HP, Rowan MC, et al. Metabolism of the new anticonvulsive trial drug rufinamide (CGP 33101) in healthy male volunteers (abstract). Epilepsia. 1996;37(Suppl 5):167.
41. Cheung WK, Kianifard F, Wong A, et al. Intra- and inter-subject variabilities of CGP 33101 after replicate single oral doses of two 200-mg tablets and 400-mg suspension. Pharm Res. 1995;12(12): 1878-1882.
42. Satoh T, Hosokawa M. Structure, function and regulation of carboxylesterases. Chem Biol Inter. 2006;162(3):195-211.
43. Chung SW, Choi L, Karoplehyk MA. A pharmacokinetic evaluation of rufinamide in elderly and younger subjects [abstract]. Epilepsia. 1998;39(Suppl 6):59.
44. Sachdeo R, Rosenfeld W, Choi L, Yeah C-M, Cooper A, Karolchyk M. Pharmacokinetics and safety of adjunctive runfinamide therapy in pediatric pateints with epilepsy (abstract). Epilepsia. 1998;39(Suppl 6): 166-167.
45. Krauss GL, Perdomo CA, Arroyo S. Short and long-term safety of rufinamide in patients with epilepsy (abstract). Epilepsia. 2005;46 (Suppl 8):205-222.
46. Fuseau E, Critchley D, Perdomo C, Arroyo S. Population pharmacokinetics drug-drug interaction analyses of rufinamide studies in patients with epilepsy. (abstract). Epilepsia. 2005;46(Suppl 8):210-211.
47. Pennell PB, Ogaily MS, Macdonald RL. Aplastic anemia in a patient receiving felbamate for complex partial seizures. Neurology. 1995;45(3 Pt 1):456-460.
48. Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia. 1999;40(7):985-991.
49. Keates E, Clark T. Acute myopia and secondary angle closure glaucoma: a rare ocular syndrome in topiramate-treated patients (abstract). Neurology 2002;58:422.
50. Ben-Zeev B, Watemberg N, Augarten A, et al. Oligohydrosis and hyperthermia: pilot study of a novel topiramate adverse effect. J Child Neurol. 2003;18(4):254-257.
51. Marchand M, Critchley D, Nagy C, Faseus E. The effect of rufinamide concentration on the QT interval in healthy subjects treated during 18 days with multiple ascending doses: a population PK/PD analysis (abstract). Annual Meeting of the Population Approach Group. Vol Pamplona, Spain; 2005.
52. Bjerregaard P, Gussak I. Short QT syndrome. Ann Noninvasive Electrocardiol. 2005;10(4):436-440.
53. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004;62(8):1261-1273.
54. Glauser T, Kluger G, Sachdeo R, et al. Open-label extension study of the efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome (abstract). Epilepsia. 2005;46(Suppl 6):408.